Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Breast cancer recurrence affects up to 30% of patients post-treatment.
• Current monitoring methods lack sensitivity and reliability for early distant metastasis detection.
• Early detection of recurrence is crucial for effective therapeutic intervention.

Purpose of the Study:

• To evaluate the efficacy of personalized circulating tumor DNA (ctDNA) profiling for detecting breast cancer recurrence.
• To assess the sensitivity and specificity of ctDNA analysis in monitoring patients for disease relapse.
• To determine the lead time provided by ctDNA detection compared to clinical recurrence.

Main Methods:

• Recruited 49 breast cancer patients post-surgery and adjuvant therapy.
• Collected 208 plasma samples over 4 years for serial ctDNA analysis.
• Utilized ultradeep sequencing of personalized assays targeting 16 tumor variants.

Main Results:

• ctDNA detected recurrence ahead of clinical relapse in 89% of patients (16/18).
• Metastatic relapse was predicted with a lead time of up to 2 years (median 8.9 months).
• 100% specificity was achieved, with no ctDNA detection in 31 non-relapsed patients.

Conclusions:

• Patient-specific ctDNA analysis is a sensitive and specific tool for breast cancer surveillance.
• Early detection of recurrence via ctDNA offers a window for therapeutic intervention.
• ctDNA profiling holds significant promise for improving patient outcomes in breast cancer management.